Outcometrix, St Petersburg, FL, USA.
Ironwood Pharmaceuticals, Inc, Boston, MA, USA.
Value Health. 2020 Mar;23(3):362-369. doi: 10.1016/j.jval.2020.01.002. Epub 2020 Feb 20.
The Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C) has been developed to assess the core signs and symptoms of irritable bowel syndrome with constipation (IBS-C). This article presents the psychometric evaluation of the DIBSS-C abdominal score.
Data for these analyses are from a multicenter phase IIb study in IBS-C patients (NCT02559206). Subjects completed a number of assessments via handheld electronic diary throughout the study. The analyses used the intent-to-treat population and were blinded to randomized treatment group. The analyses evaluated the reliability, validity, and responsiveness of the DIBSS-C abdominal score; identified an appropriate scoring algorithm; and determined thresholds for interpreting clinically meaningful changes at the individual level.
The correlations between the DIBSS-C abdominal symptom items (ie, abdominal pain, discomfort, and bloating) were strong (>0.75). Cronbach's alpha for the abdominal symptom severity items was very strong (.94), indicating that the 3 abdominal symptom items produce a reliable score. The intraclass correlation coefficient for the abdominal score was 0.82, exceeding the threshold of 0.70 and indicating good test-retest reliability. Guyatt's responsiveness statistic values all exceeded the threshold for a large effect of 0.80, so the DIBSS-C abdominal score can be considered highly responsive to change. Triangulation across 3 sets of anchor-based analyses indicated that a threshold of -2.0 points on the abdominal score is an appropriate threshold for identifying meaningful change.
Overall, this study provides evidence that the DIBSS-C abdominal score is valid, reliable, responsive to change, and interpretable for assessing treatment benefit in patients with IBS-C.
便秘型肠易激综合征症状日记(DIBSS-C)旨在评估便秘型肠易激综合征(IBS-C)的核心症状和体征。本文介绍了 DIBSS-C 腹部评分的心理计量学评估。
这些分析的数据来自于 IBS-C 患者的多中心 IIb 期研究(NCT02559206)。受试者在整个研究过程中通过手持电子日记完成了多项评估。分析采用意向治疗人群,且对随机治疗组设盲。分析评估了 DIBSS-C 腹部评分的可靠性、有效性和反应性;确定了合适的评分算法;并确定了个体水平上解释有临床意义变化的阈值。
DIBSS-C 腹部症状项目(即腹痛、不适和腹胀)之间的相关性很强(>0.75)。腹部症状严重程度项目的 Cronbach's alpha 非常强(.94),表明 3 个腹部症状项目产生可靠的评分。腹部评分的组内相关系数为 0.82,超过了 0.70 的阈值,表明测试-重测可靠性良好。Guyatt 的反应性统计值均超过了 0.80 的大效应阈值,因此 DIBSS-C 腹部评分可被认为对变化高度敏感。基于 3 组锚定分析的三角测量表明,腹部评分降低-2.0 分是识别有意义变化的合适阈值。
总的来说,这项研究提供了证据表明,DIBSS-C 腹部评分在评估 IBS-C 患者的治疗获益方面是有效、可靠、对变化敏感且可解释的。